Sahil Bade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sahil Bade has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Sohail Bade
Pain Medicine Department, Mayo Clinic, Jacksonville, FL, USA
4 shared publications - Jason Eldrige
Department of Pain Medicine, Mayo Clinic, Jacksonville, Florida, USA
2 shared publications Sahil Gupta
Mayo Clinic
2 shared publications- Sebastian Encalada
Department of Pain Medicine, Mayo Clinic, Jacksonville, FL, USA
2 shared publications Aaron Fisher
Department of Pain Medicine, Mayo Clinic, Jacksonville, FL, USA
1 shared publication- Christine Hunt
Anesthesiology - Pain Medicine, Mayo Clinic, Rochester, Minnesota, USA
1 shared publication
Latest Publications
- Open Access
- 4 April 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (2) , 100751
The utility of SPECT-CT in identifying vertebral endplate changes for basivertebral nerve ablation: A retrospective study with MRI comparison
- 4 April 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (2) , 100751
Open AccessThe utility of SPECT-CT in identifying vertebral endplate changes for basivertebral nerve ablation: A retrospective study with MRI comparison
- 28 July 2025
- Published by Taylor & Francis in Pain Management
- Vol. 15 (10) , 753-765
GLP-1 agonists: a game changer in pain treatment and addiction
Chronic pain imposes a significant healthcare burden, with treatments often limited by side effects, opioid dependency, and preventable surgeries. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), developed for diabetes and obesity, may offer novel analgesia and treat drug-seeking behavior. This review examines the role of GLP-1RAs in pain management, focusing on inflammation, macrophage repolarization, oxidative stress, and dopaminergic pathways in substance use disorders. We conducted a literature search in PubMed and Embase (Ovid) from January 2000 to February 2025, identifying studies on GLP-1RA and pain in headaches, osteoarthritis, diabetic neuropathy, and substance use disorders. GLP-1RAs offer a promising shift in pain management, potentially reducing opioid dependence, preventing surgical interventions, and lowering healthcare costs. While early evidence suggests analgesic and disease-modifying effects beyond weight loss, significant knowledge gaps remain. In osteoarthritis, they appear to reduce inflammation and cartilage degradation, but trials in non-obese, non-comorbid patients are needed. In diabetic neuropathy, GLP-1RAs show potential for nerve repair, but optimal dosing and long-term efficacy need clarification. Preclinical data support GLP-1RAs signaling in migraines, but human studies are lacking. Trials in alcohol addiction show promise, though evidence for other substances remains inconclusive. Larger-scale trials are needed to confirm these findings.
- 28 July 2025
- Published by Taylor & Francis in Pain Management
- Vol. 15 (10) , 753-765
GLP-1 agonists: a game changer in pain treatment and addiction
Chronic pain imposes a significant healthcare burden, with treatments often limited by side effects, opioid dependency, and preventable surgeries. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), developed for diabetes and obesity, may offer novel analgesia and treat drug-seeking behavior. This review examines the role of GLP-1RAs in pain management, focusing on inflammation, macrophage repolarization, oxidative stress, and dopaminergic pathways in substance use disorders. We conducted a literature search in PubMed and Embase (Ovid) from January 2000 to February 2025, identifying studies on GLP-1RA and pain in headaches, osteoarthritis, diabetic neuropathy, and substance use disorders. GLP-1RAs offer a promising shift in pain management, potentially reducing opioid dependence, preventing surgical interventions, and lowering healthcare costs. While early evidence suggests analgesic and disease-modifying effects beyond weight loss, significant knowledge gaps remain. In osteoarthritis, they appear to reduce inflammation and cartilage degradation, but trials in non-obese, non-comorbid patients are needed. In diabetic neuropathy, GLP-1RAs show potential for nerve repair, but optimal dosing and long-term efficacy need clarification. Preclinical data support GLP-1RAs signaling in migraines, but human studies are lacking. Trials in alcohol addiction show promise, though evidence for other substances remains inconclusive. Larger-scale trials are needed to confirm these findings.
- Open Access
- 18 February 2025
- Published by Elsevier in Interventional Pain Medicine
- Vol. 4 (1) , 100550
Optimizing patient understanding of spine MRI reports using AI: A prospective single center study
- 18 February 2025
- Published by Elsevier in Interventional Pain Medicine
- Vol. 4 (1) , 100550
Open AccessOptimizing patient understanding of spine MRI reports using AI: A prospective single center study
- Open Access
- 29 August 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (9) , e9403
Transformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex‐sumo wrestler
Key Clinical Message: Dulaglutide is a relatively unpopular GLP‐1 receptor agonist used for weight loss. This case demonstrates that dulaglutide may be beneficial for weight loss in morbidly obese patients with multiple comorbidities after thoroughly evaluating its efficacy, benefits, and long‐term adverse effects through clinical trials. We present a case of a 27‐year‐old ex‐sumo wrestler with bipolar II disorder, morbid obesity, hypertension, Type 2 Diabetes Mellitus (DM), and a Body Mass Index (BMI) of 49.66 kg/m2. He was non‐compliant with lifestyle modifications and resistant to conventional treatments, including metformin, and was also using multiple antipsychotic drugs. After introducing dulaglutide, he achieved a 40 kg (−21%) weight loss and a BMI reduction of 10.3 kg/m2 over 6 months, with no side effects and improved glycemic control, demonstrating dulaglutide's efficacy for weight loss in such challenging presentations.
- 29 August 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (9) , e9403
Open AccessTransformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex‐sumo wrestler
Key Clinical Message: Dulaglutide is a relatively unpopular GLP‐1 receptor agonist used for weight loss. This case demonstrates that dulaglutide may be beneficial for weight loss in morbidly obese patients with multiple comorbidities after thoroughly evaluating its efficacy, benefits, and long‐term adverse effects through clinical trials. We present a case of a 27‐year‐old ex‐sumo wrestler with bipolar II disorder, morbid obesity, hypertension, Type 2 Diabetes Mellitus (DM), and a Body Mass Index (BMI) of 49.66 kg/m2. He was non‐compliant with lifestyle modifications and resistant to conventional treatments, including metformin, and was also using multiple antipsychotic drugs. After introducing dulaglutide, he achieved a 40 kg (−21%) weight loss and a BMI reduction of 10.3 kg/m2 over 6 months, with no side effects and improved glycemic control, demonstrating dulaglutide's efficacy for weight loss in such challenging presentations.